Domainex agrees collaboration in breast cancer

Collaboration

Domainex Ltd has announced that it will collaborate with the medical charity Breakthrough Breast Cancer Research Centre and The Institute of Cancer Research to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon.

The collaboration brings together the Breakthrough Research Centre’s expertise in the genetics, biochemistry and cell biology of breast cancer and Domainex’s capability to discover drugs using its LeadBuilder hit-finding platform technology. The objective is to bring forward inhibitors of both targets to the proof of concept stage in breast cancer models and then to partner the programmes for clinical development.